Protecting your child’s health is paramount, and vaccination plays a crucial role in preventing serious diseases. One such disease is Haemophilus influenzae type b (Hib), a bacterial infection primarily affecting infants and young children. Hib can lead to severe complications, including bacterial meningitis, which causes inflammation of the brain and spinal cord’s protective membranes. Survivors of Hib meningitis may experience long-term neurological issues like intellectual disability, hearing loss, learning difficulties, motor impairments, or seizures.
Fortunately, Hib is preventable through vaccination. Thanks to widespread Hib vaccination programs, the incidence of the disease has drastically reduced. According to David Greenberg, M.D., Director, Scientific & Medical Affairs, sanofi pasteur, the success of Hib vaccination means many healthcare providers have never encountered the disease’s devastating effects. Continued on-time vaccination is essential to prevent its resurgence.
Before the introduction of Hib vaccines like ActHIB, approximately 20,000 cases occurred annually, mainly in children under five. Today, the number is fewer than 100 due to effective immunization. However, vigilance is crucial. Children can contract Hib from asymptomatic carriers, emphasizing the importance of vaccination, especially for those in daycare, with school-aged siblings, or living in large households.
Vaccination schedules typically begin between 2 and 6 months of age, followed by a booster dose between 12 and 18 months. Adhering to this schedule is vital for optimal protection. While Hib is currently rare, the risk remains, highlighting the continued importance of timely immunizations. Consult your healthcare provider or local health department for more information on Hib vaccination. Additional resources can be found at reputable medical websites.
Like all vaccines, Hib vaccines carry some risks. Potential side effects of ActHIB may include injection-site reactions (redness, swelling, tenderness) and systemic reactions (fever, irritability, drowsiness). ActHIB is not suitable for children with severe allergic reactions to vaccine components or those under six weeks old. Caution is advised for individuals with bleeding disorders due to the risk of bruising from intramuscular injections. Vaccination should be postponed in children with moderate or severe acute illnesses.